Zeynep Kalender Atak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zeynep Kalender Atak has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Stein Aerts
Laboratory of Computational Biology, VIB Center for AI & Computational Biology (VIB.AI), Leuven, Belgium
18 shared publications - Gert Hulselmans
Laboratory of Computational Biology, Department of Human Genetics, KU Leuven, Leuven, Belgium
10 shared publications - Hana Imrichova
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
7 shared publications - Jan Cools
KU Leuven
6 shared publications Valerie Christiaens
VIB-KU Leuven Center for Brain and Disease Research, 3000 Leuven, Belgium
6 shared publicationsDmitry Svetlichnyy
Laboratory of Computational Biology, VIB Center for Brain & Disease Research, Leuven, Belgium
5 shared publications
Latest Publications
- Open Access
- 19 April 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (9) , 773-784
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia
Acute leukemias (AL) of ambiguous lineage are a heterogeneous group of high-risk leukemias characterized by co-expression of myeloid and lymphoid markers. In this study, we identified a distinct subgroup of immature acute leukemias characterized by a broadly variable phenotype, covering acute myeloid leukemia (AML M0 or M1), T/myeloid mixed phenotype acute leukemia (T/M MPAL), and early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Rearrangements at 14q32/BCL11B are the cytogenetic hallmark of this entity. In our screening of 915 hematological malignancies, there were 202 AML and 333 T-cell Acute Lymphoblastic Leukemia (T-ALL) (58 ETP, 178 non-ETP, 8 T/M MPAL, 89 not otherwise specified). We identified 20 cases of immature leukemias (4% of AML and 3,6% of T-ALL) harbouring four types of 14q32/BCL11B translocations: t(2,14)(q22.3;q32) (n=7), t(6;14)(q25.3;q32) (n=9), t(7;14)(q21.2;q32) (n=2) and t(8;14)(q24.2;q32) (n=2). The t(2;14) produced a ZEB2-BCL11B fusion transcript, while the other three rearrangements displaced transcriptionally active enhancer sequences close to BCL11B without producing fusion genes. All translocations resulted in the activation of BCL11B, a regulator of T-cell differentiation associated with transcriptional corepressor complexes in mammalian cells. The expression of BCL11B behaved as a disease biomarker, which was present at diagnosis but not in remission. Deregulation of BCL11B co-occurred with variants at FLT3 and at epigenetic modulators, most frequently DNMT3A, TET2 and/or WT1 gene. Transcriptome analysis identified a specific expression signature, with significant downregulation of BCL11B targets, and clearly separating BCL11B positive AL from AML, T-ALL, and ETP-ALL. Remarkably, ex-vivo drug sensitivity profile identified a panel of compounds with effective antileukemic activity.
- 19 April 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (9) , 773-784
Open Access14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia
Acute leukemias (AL) of ambiguous lineage are a heterogeneous group of high-risk leukemias characterized by co-expression of myeloid and lymphoid markers. In this study, we identified a distinct subgroup of immature acute leukemias characterized by a broadly variable phenotype, covering acute myeloid leukemia (AML M0 or M1), T/myeloid mixed phenotype acute leukemia (T/M MPAL), and early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Rearrangements at 14q32/BCL11B are the cytogenetic hallmark of this entity. In our screening of 915 hematological malignancies, there were 202 AML and 333 T-cell Acute Lymphoblastic Leukemia (T-ALL) (58 ETP, 178 non-ETP, 8 T/M MPAL, 89 not otherwise specified). We identified 20 cases of immature leukemias (4% of AML and 3,6% of T-ALL) harbouring four types of 14q32/BCL11B translocations: t(2,14)(q22.3;q32) (n=7), t(6;14)(q25.3;q32) (n=9), t(7;14)(q21.2;q32) (n=2) and t(8;14)(q24.2;q32) (n=2). The t(2;14) produced a ZEB2-BCL11B fusion transcript, while the other three rearrangements displaced transcriptionally active enhancer sequences close to BCL11B without producing fusion genes. All translocations resulted in the activation of BCL11B, a regulator of T-cell differentiation associated with transcriptional corepressor complexes in mammalian cells. The expression of BCL11B behaved as a disease biomarker, which was present at diagnosis but not in remission. Deregulation of BCL11B co-occurred with variants at FLT3 and at epigenetic modulators, most frequently DNMT3A, TET2 and/or WT1 gene. Transcriptome analysis identified a specific expression signature, with significant downregulation of BCL11B targets, and clearly separating BCL11B positive AL from AML, T-ALL, and ETP-ALL. Remarkably, ex-vivo drug sensitivity profile identified a panel of compounds with effective antileukemic activity.
- Open Access
- 8 April 2021
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 31 (6) , 1082-1096
Interpretation of allele-specific chromatin accessibility using cell state–aware deep learning
Genomic sequence variation within enhancers and promoters can have a significant impact on the cellular state and phenotype. However, sifting through the millions of candidate variants in a personal genome or a cancer genome, to identify those that impact cis-regulatory function, remains a major challenge. Interpretation of noncoding genome variation benefits from explainable artificial intelligence to predict and interpret the impact of a mutation on gene regulation. Here we generate phased whole genomes with matched chromatin accessibility, histone modifications, and gene expression for 10 melanoma cell lines. We find that training a specialized deep learning model, called DeepMEL2, on melanoma chromatin accessibility data can capture the various regulatory programs of the melanocytic and mesenchymal-like melanoma cell states. This model outperforms motif-based variant scoring, as well as more generic deep learning models. We detect hundreds to thousands of allele-specific chromatin accessibility variants (ASCAVs) in each melanoma genome, of which 15%–20% can be explained by gains or losses of transcription factor binding sites. A considerable fraction of ASCAVs are caused by changes in AP-1 binding, as confirmed by matched ChIP-seq data to identify allele-specific binding of JUN and FOSL1. Finally, by augmenting the DeepMEL2 model with ChIP-seq data for GABPA, the TERT promoter mutation, as well as additional ETS motif gains, can be identified with high confidence. In conclusion, we present a new integrative genomics approach and a deep learning model to identify and interpret functional enhancer mutations with allelic imbalance of chromatin accessibility and gene expression.
- 8 April 2021
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 31 (6) , 1082-1096
Open AccessInterpretation of allele-specific chromatin accessibility using cell state–aware deep learning
Genomic sequence variation within enhancers and promoters can have a significant impact on the cellular state and phenotype. However, sifting through the millions of candidate variants in a personal genome or a cancer genome, to identify those that impact cis-regulatory function, remains a major challenge. Interpretation of noncoding genome variation benefits from explainable artificial intelligence to predict and interpret the impact of a mutation on gene regulation. Here we generate phased whole genomes with matched chromatin accessibility, histone modifications, and gene expression for 10 melanoma cell lines. We find that training a specialized deep learning model, called DeepMEL2, on melanoma chromatin accessibility data can capture the various regulatory programs of the melanocytic and mesenchymal-like melanoma cell states. This model outperforms motif-based variant scoring, as well as more generic deep learning models. We detect hundreds to thousands of allele-specific chromatin accessibility variants (ASCAVs) in each melanoma genome, of which 15%–20% can be explained by gains or losses of transcription factor binding sites. A considerable fraction of ASCAVs are caused by changes in AP-1 binding, as confirmed by matched ChIP-seq data to identify allele-specific binding of JUN and FOSL1. Finally, by augmenting the DeepMEL2 model with ChIP-seq data for GABPA, the TERT promoter mutation, as well as additional ETS motif gains, can be identified with high confidence. In conclusion, we present a new integrative genomics approach and a deep learning model to identify and interpret functional enhancer mutations with allelic imbalance of chromatin accessibility and gene expression.
- Open Access
Prioritization of enhancer mutations by combining allele-specific chromatin accessibility with deep learning
Brief Prioritization of non-coding genome variation benefits from explainable AI to predict and interpret the impact of a mutation on gene regulation. Here we apply a specialized deep learning model to phased melanoma genomes and identify functional enhancer mutations with allelic imbalance of chromatin accessibility and gene expression.
Open AccessPrioritization of enhancer mutations by combining allele-specific chromatin accessibility with deep learning
Brief Prioritization of non-coding genome variation benefits from explainable AI to predict and interpret the impact of a mutation on gene regulation. Here we apply a specialized deep learning model to phased melanoma genomes and identify functional enhancer mutations with allelic imbalance of chromatin accessibility and gene expression.
- Open Access
Single-cell gene regulatory network analysis reveals new melanoma cell states and transition trajectories during phenotype switching
Melanoma is notorious for its cellular heterogeneity, which is at least partly due to its ability to transition between alternate cell states. Similarly to EMT, melanoma cells with a melanocytic phenotype can switch to a mesenchymal-like phenotype. However, scattered emerging evidence indicates that additional, intermediate state(s) may exist. In order to search for such new melanoma states and decipher their underlying gene regulatory network (GRN), we extensively studied ten patient-derived melanoma cultures by single-cell RNA-seq of >39,000 cells. Although each culture exhibited a unique transcriptome, we identified shared gene regulatory networks that underlie the extreme melanocytic and mesenchymal cell states, as well as one (stable) intermediate state. The intermediate state was corroborated by a distinct open chromatin landscape and governed by the transcription factors EGR3, NFATC2, and RXRG. Single-cell migration assays established that this “transition” state exhibits an intermediate migratory phenotype. Through a dense time-series sampling of single cells and dynamic GRN inference, we unraveled the sequential and recurrent arrangement of transcriptional programs at play during phenotype switching that ultimately lead to the mesenchymal cell state. We provide the scRNA-Seq data with 39,263 melanoma cells on our SCope platform and the ATAC-seq data on a UCSC hub to jointly serve as a resource for the melanoma field. Together, this exhaustive analysis of melanoma cell state diversity indicates that additional states exists between the two extreme melanocytic and mesenchymal-like states. The GRN we identified may serve as a new putative target to prevent the switch to mesenchymal cell state and thereby, acquisition of metastatic and drug resistant potential.
Open AccessSingle-cell gene regulatory network analysis reveals new melanoma cell states and transition trajectories during phenotype switching
Melanoma is notorious for its cellular heterogeneity, which is at least partly due to its ability to transition between alternate cell states. Similarly to EMT, melanoma cells with a melanocytic phenotype can switch to a mesenchymal-like phenotype. However, scattered emerging evidence indicates that additional, intermediate state(s) may exist. In order to search for such new melanoma states and decipher their underlying gene regulatory network (GRN), we extensively studied ten patient-derived melanoma cultures by single-cell RNA-seq of >39,000 cells. Although each culture exhibited a unique transcriptome, we identified shared gene regulatory networks that underlie the extreme melanocytic and mesenchymal cell states, as well as one (stable) intermediate state. The intermediate state was corroborated by a distinct open chromatin landscape and governed by the transcription factors EGR3, NFATC2, and RXRG. Single-cell migration assays established that this “transition” state exhibits an intermediate migratory phenotype. Through a dense time-series sampling of single cells and dynamic GRN inference, we unraveled the sequential and recurrent arrangement of transcriptional programs at play during phenotype switching that ultimately lead to the mesenchymal cell state. We provide the scRNA-Seq data with 39,263 melanoma cells on our SCope platform and the ATAC-seq data on a UCSC hub to jointly serve as a resource for the melanoma field. Together, this exhaustive analysis of melanoma cell state diversity indicates that additional states exists between the two extreme melanocytic and mesenchymal-like states. The GRN we identified may serve as a new putative target to prevent the switch to mesenchymal cell state and thereby, acquisition of metastatic and drug resistant potential.
- 28 June 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (12) , e585-e589
A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing
- 28 June 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (12) , e585-e589
A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing
- Open Access
- 24 December 2017
- Published by Akademik Gida in Akademik Gıda
- Vol. 15 (4) , 416-425
Gıda Endüstrisinde Aroma Mikroenkapsülasyonu
Tr en Tüketici tercihlerini büyük ölçüde etkileyen ve ekonomik açıdan değerli olan aromalar, gıda endüstrisinde önemli bir yer tutmaktadır. Hassas ve uçucu olan bu değerli bileşenler, monomerler veya polimerler gibi kaplama materyallerinden oluşan kabuk ya da matrislerle enkapsüle edilebilmektedir. Oda sıcaklığında genellikle sıvı halde olan aroma bileşenlerinin enkapsülasyonu ile toz formda ürün elde edilirken, çevresel etkenlerden koruma ve raf ömründe artış gibi avantajlar sağlanabilmektedir. Aromaların enkapsülasyonunda püskürterek kurutma, püskürterek soğutma, ekstrüzyon, dondurarak kurutma, koaservasyon ve moleküler hapsetme gibi teknolojiler kullanılmaktadır. Bu derlemede, gıda endüstrisinde kullanılan aromaların çeşitli teknolojilerle enkapsülasyonu ile ilgili olarak yapılan çalışmalar incelenmiştir. Aroma, which has a great influence on consumer preferences and economic value, has an important place in food industry. These volatile and sensitive valuable components can be encapsulated with shells or matrices of coating materials such as monomers or polymers. The encapsulation of aroma components, which are usually liquid at room temperatures, can provide advantages such as protection from environmental factors and increased shelf life when the product is in a powder form. Techniques such as spray drying, spray cooling, extrusion, freeze drying, coacervation and molecular inclusion are used in the encapsulation of aroma components. In this study, studies on the encapsulation of aroma components with various technologies used in food industry are reviewed.
- 24 December 2017
- Published by Akademik Gida in Akademik Gıda
- Vol. 15 (4) , 416-425
Open AccessGıda Endüstrisinde Aroma Mikroenkapsülasyonu
Tr en Tüketici tercihlerini büyük ölçüde etkileyen ve ekonomik açıdan değerli olan aromalar, gıda endüstrisinde önemli bir yer tutmaktadır. Hassas ve uçucu olan bu değerli bileşenler, monomerler veya polimerler gibi kaplama materyallerinden oluşan kabuk ya da matrislerle enkapsüle edilebilmektedir. Oda sıcaklığında genellikle sıvı halde olan aroma bileşenlerinin enkapsülasyonu ile toz formda ürün elde edilirken, çevresel etkenlerden koruma ve raf ömründe artış gibi avantajlar sağlanabilmektedir. Aromaların enkapsülasyonunda püskürterek kurutma, püskürterek soğutma, ekstrüzyon, dondurarak kurutma, koaservasyon ve moleküler hapsetme gibi teknolojiler kullanılmaktadır. Bu derlemede, gıda endüstrisinde kullanılan aromaların çeşitli teknolojilerle enkapsülasyonu ile ilgili olarak yapılan çalışmalar incelenmiştir. Aroma, which has a great influence on consumer preferences and economic value, has an important place in food industry. These volatile and sensitive valuable components can be encapsulated with shells or matrices of coating materials such as monomers or polymers. The encapsulation of aroma components, which are usually liquid at room temperatures, can provide advantages such as protection from environmental factors and increased shelf life when the product is in a powder form. Techniques such as spray drying, spray cooling, extrusion, freeze drying, coacervation and molecular inclusion are used in the encapsulation of aroma components. In this study, studies on the encapsulation of aroma components with various technologies used in food industry are reviewed.
- Top Cited PapersOpen Access
- 9 October 2017
- Published by Springer Nature in Nature Methods
- Vol. 14 (11) , 1083-1086
SCENIC: single-cell regulatory network inference and clustering
SCENIC enables simultaneous regulatory network inference and robust cell clustering from single-cell RNA-seq data. We present SCENIC, a computational method for simultaneous gene regulatory network reconstruction and cell-state identification from single-cell RNA-seq data ( http://scenic.aertslab.org ). On a compendium of single-cell data from tumors and brain, we demonstrate that cis-regulatory analysis can be exploited to guide the identification of transcription factors and cell states. SCENIC provides critical biological insights into the mechanisms driving cellular heterogeneity.
- 9 October 2017
- Published by Springer Nature in Nature Methods
- Vol. 14 (11) , 1083-1086
Top Cited PapersOpen AccessSCENIC: single-cell regulatory network inference and clustering
SCENIC enables simultaneous regulatory network inference and robust cell clustering from single-cell RNA-seq data. We present SCENIC, a computational method for simultaneous gene regulatory network reconstruction and cell-state identification from single-cell RNA-seq data ( http://scenic.aertslab.org ). On a compendium of single-cell data from tumors and brain, we demonstrate that cis-regulatory analysis can be exploited to guide the identification of transcription factors and cell states. SCENIC provides critical biological insights into the mechanisms driving cellular heterogeneity.
- Open Access
- 30 August 2017
- Published by Springer Nature in Genome Medicine
- Vol. 9 (1) , 1-13
Identification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks
The identification of functional non-coding mutations is a key challenge in the field of genomics. Here we introduce μ-cisTarget to filter, annotate and prioritize cis-regulatory mutations based on their putative effect on the underlying “personal” gene regulatory network. We validated μ-cisTarget by re-analyzing the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma. Next, we re-sequenced the full genomes of ten cancer cell lines and used matched transcriptome data and motif discovery to identify master regulators with de novo binding sites that result in the up-regulation of nearby oncogenic drivers. μ-cisTarget is available from http://mucistarget.aertslab.org .
- 30 August 2017
- Published by Springer Nature in Genome Medicine
- Vol. 9 (1) , 1-13
Open AccessIdentification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks
The identification of functional non-coding mutations is a key challenge in the field of genomics. Here we introduce μ-cisTarget to filter, annotate and prioritize cis-regulatory mutations based on their putative effect on the underlying “personal” gene regulatory network. We validated μ-cisTarget by re-analyzing the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma. Next, we re-sequenced the full genomes of ten cancer cell lines and used matched transcriptome data and motif discovery to identify master regulators with de novo binding sites that result in the up-regulation of nearby oncogenic drivers. μ-cisTarget is available from http://mucistarget.aertslab.org .
- 1 April 2017
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 43, 82-92
Decoding transcriptional states in cancer
- 1 April 2017
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 43, 82-92
Decoding transcriptional states in cancer
- Open Access
- 18 May 2016
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 26 (7) , 882-895
Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic
Transcription factors regulate their target genes by binding to regulatory regions in the genome. Although the binding preferences of TP53 are known, it remains unclear what distinguishes functional enhancers from nonfunctional binding. In addition, the genome is scattered with recognition sequences that remain unoccupied. Using two complementary techniques of multiplex enhancer-reporter assays, we discovered that functional enhancers could be discriminated from nonfunctional binding events by the occurrence of a single TP53 canonical motif. By combining machine learning with a meta-analysis of TP53 ChIP-seq data sets, we identified a core set of more than 1000 responsive enhancers in the human genome. This TP53 cistrome is invariably used between cell types and experimental conditions, whereas differences among experiments can be attributed to indirect nonfunctional binding events. Our data suggest that TP53 enhancers represent a class of unsophisticated cell-autonomous enhancers containing a single TP53 binding site, distinct from complex developmental enhancers that integrate signals from multiple transcription factors.
- 18 May 2016
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 26 (7) , 882-895
Open AccessMultiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic
Transcription factors regulate their target genes by binding to regulatory regions in the genome. Although the binding preferences of TP53 are known, it remains unclear what distinguishes functional enhancers from nonfunctional binding. In addition, the genome is scattered with recognition sequences that remain unoccupied. Using two complementary techniques of multiplex enhancer-reporter assays, we discovered that functional enhancers could be discriminated from nonfunctional binding events by the occurrence of a single TP53 canonical motif. By combining machine learning with a meta-analysis of TP53 ChIP-seq data sets, we identified a core set of more than 1000 responsive enhancers in the human genome. This TP53 cistrome is invariably used between cell types and experimental conditions, whereas differences among experiments can be attributed to indirect nonfunctional binding events. Our data suggest that TP53 enhancers represent a class of unsophisticated cell-autonomous enhancers containing a single TP53 binding site, distinct from complex developmental enhancers that integrate signals from multiple transcription factors.